Log In
Print
BCIQ
Print
Print this Print this
 

Iclusig, ponatinib (formerly AP24534)

Also known as: 534

  Manage Alerts
Collapse Summary General Information
Company Ariad Pharmaceuticals Inc.
DescriptionPan-BCR-ABL tyrosine kinase inhibitor (TKI)
Molecular Target BCR-ABL tyrosine kinase ; FMS-like tyrosine kinase 3 (FLT3) (CD135)
Mechanism of ActionVascular endothelial growth factor (VEGF) inhibitor; BCR-ABL tyrosine kinase inhibitor; Tyrosine kinase receptor 2 (Tie2) inhibitor; Fibroblast growth factor (FGF) receptor (FGFR) antagonist
Therapeutic ModalitySmall molecule

 Product Details
Disease CategoryStandard IndicationIndication DetailsPartnersMilestonesLatest Stage of DevelopmentRegulatory Designation
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

6

$107.3M

$177.5M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today